Phase 3 trial in 443 patients with untreated PD-L1-positive advanced triple-negative breast cancer: sacituzumab govitecan plus pembrolizumab improved median PFS vs chemotherapy plus pembrolizumab (11.2 vs 7.8 months; HR 0.65); OS immature.
RCTn = 443
Tolaney et al. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer